Xagrid Den europeiske union - norsk - EMA (European Medicines Agency)

xagrid

takeda pharmaceuticals international ag ireland branch - anagrelide - trombocytemi, essensielt - antineoplastiske midler - xagrid angis for reduksjon av opphøyet platederivert teller i risikosonen essensielle-thrombocythaemia (et) pasienter som er intolerante for deres nåværende terapi eller med forhøyet platederivert teller ikke reduseres til et akseptabelt nivå av deres nåværende behandling. en risiko patientan på risiko og er definert av ett eller flere av følgende funksjoner:>60 år eller;en blodplater >1000 x 109/l eller;en historie av thrombohaemorrhagic arrangementer.

Dexamfetamine esspharm 1 mg/ ml Norge - norsk - Statens legemiddelverk

dexamfetamine esspharm 1 mg/ ml

taw pharma (ireland) ltd - deksamfetaminsulfat - mikstur, oppløsning - 1 mg/ ml

Bloxazoc 25 mg Norge - norsk - Statens legemiddelverk

bloxazoc 25 mg

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 25 mg

Bloxazoc 50 mg Norge - norsk - Statens legemiddelverk

bloxazoc 50 mg

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 50 mg

Bloxazoc 100 mg Norge - norsk - Statens legemiddelverk

bloxazoc 100 mg

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 100 mg

Bloxazoc 200 mg Norge - norsk - Statens legemiddelverk

bloxazoc 200 mg

krka, d.d. novo mesto - metoprololsuksinat - depottablett - 200 mg

Amzolynic 500 mg Norge - norsk - Statens legemiddelverk

amzolynic 500 mg

macure pharma aps - azitromycindihydrat - pulver til konsentrat til infusjonsvæske, oppløsning - 500 mg

Zolsketil pegylated liposomal Den europeiske union - norsk - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Malarone 250 mg / 100 mg Norge - norsk - Statens legemiddelverk

malarone 250 mg / 100 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg

Malarone Junior 62.5 mg / 25 mg Norge - norsk - Statens legemiddelverk

malarone junior 62.5 mg / 25 mg

glaxosmithkline as - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 62.5 mg / 25 mg